Navigation Links
Angiotech Pharmaceuticals announces time change of conference call and webcast
Date:2/24/2009

VANCOUVER, Feb. 24 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced a time change of its fourth quarter and year end conference call. The call will take place at 10:00 AM ET (7:00 AM PT) on Thursday, March 5, 2009.

    Dial information for the earnings call on March 5, 2009 has not changed
    and is as follows:

    North America (toll-free): (800) 291-9234
    International: (617) 614-3923
    Enter passcode: 52474180

A live webcast of the earnings conference call will be available to all interested parties through Angiotech's website at www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the conference call on March 5 at approximately 8:00 AM ET (5:00 AM Pacific).

A replay archive of the conference call will be available until March 12, 2009.

    Replay information is as follows:

    North America: (888) 286-8010
    International: (617) 801-6888
    Enter passcode: 36405359

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP) please visit our website at www.angiotech.com.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1

Related biology technology :

1. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
2. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
3. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
4. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
5. Angiotech wins before the UK House of Lords
6. Angiotech to Establish Separate Operating and Royalty Businesses
7. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
8. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
9. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
10. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
11. Angiotech appoints Hank McKinnell to its Board of Directors

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...SINGAPORE, Dec. 2 S*BIO Pte Ltd to... JAK2 inhibitor, SB1518, at The American Society o... New Orleans. ,, Data will be presented on the ...trial of SB1518 detailing its safety, tolerability...le in dose levels ranging from 100 to 600 mg. Thes...
(Date:12/2/2009)... SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world i...n turmoil and uncertainty is part of many,business...dustry has been,relatively immune to the economic ... , During the midst of the difficult time...; Johnson inaugurated an R&D center in Shangha...
(Date:12/1/2009)... VILLAGE, Nev., Dec. 1 P...nounced revenue guidance for the fourth quarter en..., as compared with $69 million for the fourth quar...ts was the first of two installment payments of $1... quarter 2008 results was a one-time $1.8 million ...
(Date:12/1/2009)...TH, Mass., Dec. 1 Harvest Technolo... results from the company sponsored 60-patient cli...enter in Chennai, India using the company,s BMAC S...ritical Limb Ischemia (CLI). Sri Ramachandra Medic...iated institution based in Chennai, India and one ...
Breaking Biology Technology:S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 2PDL BioPharma Provides Fourth Quarter 2009 Revenue Guidance of Approximately $57 Million 3Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 2Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia 3
...fications, thereby providing scientists with a too...duction to drug discovery. However, this sophistic...ing the threat of engineered pathogens. New resear...ome Biology shows that computational tools could b...ally engineered bacteria in environmental samples....
...ISE, Fla., March 17 Bioheart, Inc.,(Nasdaq: BHRT...elop,autologous (patient-derived) cell therapies a...heart damage, today announced that company founder...transition from Executive,Chairman and become Chai...,serves as the company,s Chief Technology Officer ...
...rch 19 at 10:00 AM EDT, CEDAR KNOLLS, N.J., March... today announced its financial results for,the fou...isphere will host a conference call to discuss fou...ch 19, 2008. A live webcast of the conference,call...: http://www.emisphere.com .,The live conference ...
Other Biology Technology:On the trail of rogue genetically modified pathogens 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 2Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 3Bioheart Founder, Howard J. Leonhardt, Becomes Chairman of the Board of Directors 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 2Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 3Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 4Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 5Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 6Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 7Emisphere Technologies, Inc. Announces 2007 Fourth Quarter and Year End Financial Results 8
(Date:12/2/2009)..., , REDWOOD CITY, Calif., Dec. 2 /PRNews...rint identity and authentication solutions, today ...del of its DigitalPersona biometric fingerprint te...gitalPersona U.are.U® 4500HD offering allows ...kly identify users so that specific transactions c...
(Date:12/2/2009)..., , Before one of your muscles can twitch, before... nerve, a tiny floodgate of sortscalled an ion cha... organs to let in the chemical signals that spur t...nstitute of Standards and Technology (NIST) has al...e surface membrane for the first time, potentially...
(Date:12/2/2009)..., New York, NY, December 2, 2009 Commonly prescr...ment of asthma in pregnant women as well as pre-te...trum disorders, psychiatric pathology, cognitive p...ren, according to a new study published in the Dec...trics & Gynecology . , Beta 2 adrenergic agonist...
Breaking Biology News(10 mins):DigitalPersona Fingerprint Sensor Technology Ships on IBM SurePOS 500 Retail Systems 2Nervy research: Researchers take initial look at ion channels in a model system 2Treatments for asthma and pre-term labor may increase risk of autism in developing fetus 2IH Systems RIVA Top Pick for Directors of Pharmacy 57370 1IH Systems RIVA Top Pick for Directors of Pharmacy 57370 2HMS Awarded Third Party Liability Services Contract by Minnesota 57366 1Dr Drew and Drug Czar Host Online Chat 57362 1
...009) The Michael & Susan Dell Center for Advancem...chool of Public Health Austin Regional Campus will...eship in Child Health at 1:30 p.m. Thursday, April...e Center Amphitheater in Austin. , Obesity expe...biostatistics and epidemiology at the University o...
...astatic prostate cancer has shown considerable pro...hose disease has become resistant to current drugs...gues at several other institutions, including Memo... new drug to treat a particularly lethal form of t... cancer, or CRPC. Also referred to as hormone-refr...
...9, 2009 -- Four experts in soil carbon research, f...tunity farmers and foresters have to manage soil c...ate in voluntary markets. Agricultural and forest ...50 million metric tons of carbon dioxide (CO 2 ) e... gas emissions. , The briefing, "Down to Earth Ca...
Other Biology News:Annual Michael & Susan Dell lectureship in child health 2New drug shows promise in treating drug-resistant prostate cancer 2New drug shows promise in treating drug-resistant prostate cancer 3New drug shows promise in treating drug-resistant prostate cancer 4Down to Earth carbon science: Briefing April 15 in DC 2
Hybridization Buffer from BD Biosciences Pharmingen
Chicken Anti-Plants Thaumatin 2 Polyclonal Antibody, Unconjugated from Abcam
Proteinase K Buffer from BD Biosciences Pharmingen
Rabbit Anti-VEGF Receptor 2, phospho (Tyr1214) Polyclonal Antibody, Unconjugated from Abcam
Biology Products: